A detailed history of Charles Schwab Investment Management Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 824,443 shares of NVCR stock, worth $25.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
824,443
Previous 808,104 2.02%
Holding current value
$25.5 Million
Previous $13.8 Million 6.91%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.61 - $23.34 $255,051 - $381,352
16,339 Added 2.02%
824,443 $12.9 Million
Q2 2024

Aug 12, 2024

BUY
$11.83 - $24.05 $3.28 Million - $6.66 Million
277,049 Added 52.17%
808,104 $13.8 Million
Q1 2024

May 08, 2024

SELL
$12.42 - $17.29 $257,342 - $358,248
-20,720 Reduced 3.76%
531,055 $8.3 Million
Q4 2023

Feb 06, 2024

BUY
$11.13 - $15.78 $116,976 - $165,847
10,510 Added 1.94%
551,775 $8.24 Million
Q3 2023

Nov 08, 2023

SELL
$16.15 - $42.35 $32,106 - $84,191
-1,988 Reduced 0.37%
541,265 $8.74 Million
Q2 2023

Aug 09, 2023

BUY
$40.29 - $82.51 $241,095 - $493,739
5,984 Added 1.11%
543,253 $22.5 Million
Q1 2023

May 11, 2023

BUY
$56.44 - $118.81 $226,945 - $477,735
4,021 Added 0.75%
537,269 $32.3 Million
Q4 2022

Feb 13, 2023

BUY
$63.98 - $85.37 $1.34 Million - $1.78 Million
20,867 Added 4.07%
533,248 $39.1 Million
Q3 2022

Nov 14, 2022

BUY
$67.99 - $89.57 $476,405 - $627,616
7,007 Added 1.39%
512,381 $38.9 Million
Q2 2022

Aug 15, 2022

BUY
$56.6 - $89.9 $795,399 - $1.26 Million
14,053 Added 2.86%
505,374 $35.1 Million
Q1 2022

May 13, 2022

BUY
$60.15 - $84.52 $633,680 - $890,418
10,535 Added 2.19%
491,321 $40.7 Million
Q4 2021

Feb 11, 2022

BUY
$75.08 - $121.99 $803,130 - $1.3 Million
10,697 Added 2.28%
480,786 $36.1 Million
Q3 2021

Nov 16, 2021

SELL
$116.17 - $194.55 $19.5 Million - $32.7 Million
-168,041 Reduced 26.33%
470,089 $54.6 Million
Q2 2021

Aug 16, 2021

BUY
$130.4 - $225.58 $2.04 Million - $3.53 Million
15,631 Added 2.51%
638,130 $142 Million
Q1 2021

May 17, 2021

BUY
$124.11 - $190.17 $5.83 Million - $8.93 Million
46,971 Added 8.16%
622,499 $82.3 Million
Q4 2020

Feb 16, 2021

SELL
$112.16 - $174.14 $1.05 Million - $1.64 Million
-9,406 Reduced 1.61%
575,528 $99.6 Million
Q3 2020

Nov 13, 2020

BUY
$58.05 - $111.31 $31.7 Million - $60.9 Million
546,766 Added 1432.52%
584,934 $65.1 Million
Q2 2020

Aug 14, 2020

SELL
$57.2 - $74.41 $9.1 Million - $11.8 Million
-159,005 Reduced 80.64%
38,168 $2.26 Million
Q1 2020

May 15, 2020

BUY
$57.05 - $95.75 $16,088 - $27,001
282 Added 0.14%
197,173 $13.3 Million
Q4 2019

Feb 07, 2020

BUY
$68.3 - $93.8 $233,176 - $320,233
3,414 Added 1.76%
196,891 $16.6 Million
Q3 2019

Nov 08, 2019

BUY
$61.86 - $97.8 $1.06 Million - $1.67 Million
17,062 Added 9.67%
193,477 $14.5 Million
Q2 2019

Aug 09, 2019

BUY
$42.22 - $63.23 $1.2 Million - $1.8 Million
28,517 Added 19.28%
176,415 $11.2 Million
Q1 2019

May 14, 2019

BUY
$31.96 - $56.12 $167,246 - $293,675
5,233 Added 3.67%
147,898 $7.13 Million
Q4 2018

Feb 14, 2019

BUY
$28.72 - $52.63 $100,520 - $184,205
3,500 Added 2.52%
142,665 $4.78 Million
Q3 2018

Nov 13, 2018

BUY
$32.0 - $52.4 $168,480 - $275,886
5,265 Added 3.93%
139,165 $7.29 Million
Q2 2018

Aug 08, 2018

BUY
$19.85 - $32.0 $621,305 - $1 Million
31,300 Added 30.51%
133,900 $4.19 Million
Q1 2018

May 07, 2018

BUY
$19.3 - $23.65 $67,550 - $82,775
3,500 Added 3.53%
102,600 $2.24 Million
Q4 2017

Jan 17, 2018

BUY
$16.3 - $21.9 $34,230 - $45,990
2,100 Added 2.16%
99,100 $2 Million
Q3 2017

Nov 13, 2017

BUY
$18.05 - $21.75 $1.75 Million - $2.11 Million
97,000
97,000 $1.93 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.25B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.